Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial
Authors
Keywords
-
Journal
NEPHROLOGY DIALYSIS TRANSPLANTATION
Volume -, Issue -, Pages -
Publisher
Oxford University Press (OUP)
Online
2022-02-24
DOI
10.1093/ndt/gfac040
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy
- (2021) David C. Wheeler et al. KIDNEY INTERNATIONAL
- Cardiac, renal, and metabolic effects of sodium–glucose co‐transporter 2 inhibitors: a position paper from the European Society of Cardiology ad‐hoc task force on sodium–glucose co‐transporter 2 inhibitors
- (2021) William G. Herrington et al. EUROPEAN JOURNAL OF HEART FAILURE
- Empagliflozin in Heart Failure with a Preserved Ejection Fraction
- (2021) Stefan D. Anker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Acute Treatment Effects on GFR in Randomized Clinical Trials of Kidney Disease Progression
- (2021) Brendon L. Neuen et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial
- (2021) David C Wheeler et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- The tubular hypothesis of nephron filtration and diabetic kidney disease
- (2020) Volker Vallon et al. Nature Reviews Nephrology
- Different eGFR Decline Thresholds and Renal Effects of Canagliflozin: Data from the CANVAS Program
- (2020) Megumi Oshima et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights from the EMPEROR-Reduced Trial
- (2020) Faiez Zannad et al. CIRCULATION
- Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients with Heart Failure with Reduced Ejection Fraction: Results of DAPA-HF
- (2020) Pardeep S. Jhund et al. CIRCULATION
- International consensus definitions of clinical trial outcomes for kidney failure: 2020
- (2020) Adeera Levin et al. KIDNEY INTERNATIONAL
- The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics
- (2020) David C Wheeler et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
- (2020) Milton Packer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dapagliflozin in Patients with Chronic Kidney Disease
- (2020) Hiddo J.L. Heerspink et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial
- (2020) David C Wheeler et al. Lancet Diabetes & Endocrinology
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Choice of endpoint in kidney outcome trials: considerations from the EMPA-REG OUTCOME® trial
- (2019) Vlado Perkovic et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis
- (2019) Brendon L Neuen et al. Lancet Diabetes & Endocrinology
- Kidney disease trials for the 21st century: innovations in design and conduct
- (2019) William G. Herrington et al. Nature Reviews Nephrology
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment
- (2017) Lennart Tonneijck et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease—Improving Global Outcomes (KDIGO) Controversies Conference
- (2017) Colin Baigent et al. KIDNEY INTERNATIONAL
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Kidney function and sudden cardiac death in the community: The Atherosclerosis Risk in Communities (ARIC) Study
- (2016) Takeki Suzuki et al. AMERICAN HEART JOURNAL
- Enhancing clinical evidence by proactively building quality into clinical trials
- (2016) Ann Meeker-O’Connell et al. Clinical Trials
- Shift to Fatty Substrate Utilization in Response to Sodium–Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes
- (2016) Ele Ferrannini et al. DIABETES
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials
- (2016) Lancet Diabetes & Endocrinology
- Association between obesity and glomerular hyperfiltration: the confounding effect of smoking and sodium and protein intakes
- (2015) Adam Ogna et al. EUROPEAN JOURNAL OF NUTRITION
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evaluating the Contribution of the Cause of Kidney Disease to Prognosis in CKD: Results From the Study of Heart and Renal Protection (SHARP)
- (2014) Richard Haynes et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- GFR Decline as an End Point for Clinical Trials in CKD: A Scientific Workshop Sponsored by the National Kidney Foundation and the US Food and Drug Administration
- (2014) Andrew S. Levey et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- A New Equation to Estimate Glomerular Filtration Rate
- (2013) Andrew S. Levey et al. ANNALS OF INTERNAL MEDICINE
- Chronic kidney disease: global dimension and perspectives
- (2013) Vivekanand Jha et al. LANCET
- Canagliflozin: Effects in overweight and obese subjects without diabetes mellitus
- (2013) Harold E. Bays et al. Obesity
- Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials
- (2013) BMJ-British Medical Journal
- Associations between Kidney Function and Subclinical Cardiac Abnormalities in CKD
- (2012) M. Park et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis
- (2012) Caroline S Fox et al. LANCET
- Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study
- (2012) Marcello Tonelli et al. LANCET
- Glomerular hyperfiltration: definitions, mechanisms and clinical implications
- (2012) Imed Helal et al. Nature Reviews Nephrology
- Chronic kidney disease
- (2011) Andrew S Levey et al. LANCET
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started